文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]FDG PET/CT用于腹膜后纤维化的治疗监测与进展预测

[18F]FDG PET/CT for treatment monitoring and prediction of progression in retroperitoneal fibrosis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-14

本研究纳入50例腹膜后纤维化患者,至少接受两次[18F]FDG PET/CT(基线BL和第一次随访FU1),36例接受第二次随访(FU2),18例接受第三次随访(FU3),评估PET与CT的治疗反应及基线参数对进展的早期预测价值。结果显示所有PET参数与腹膜后肿块厚度(CTrim)在各时间点均显著相关,治疗后所有PET参数和CTrim均显著下降(p ≤ 0.021),泼尼松龙组和联合治疗组代谢与形态学反应高度显著(分别为p ≤ 0.003和p ≤ 0.001)。FU2时8例进展,基线MAV是进展的良好预测因子(p = 0.041;进展组217.33 ml vs 非进展组100.86 ml),FU2时SUVmax、SUVpeak和MAV在进展组与非进展组间差异显著(p ≤ 0.009),而CT无显著差异。

要点

  • 治疗后所有PET参数和CTrim均显著下降(p ≤ 0.021),泼尼松龙组和联合治疗组反应高度显著。
  • FU2时8例进展,基线MAV是进展的良好预测因子(p = 0.041;217.33 ml vs 100.86 ml)。
  • FU2时SUVmax、SUVpeak和MAV在进展组与非进展组间差异显著(p ≤ 0.009),CT无显著差异。

核心结论

  • 研究结果强调PET在腹膜后纤维化治疗监测方面优于CT,尤其在FU2时检测进展方面。
  • 较高的基线MAV与FU2时进展相关,提示其作为预测标志物的潜力。
  • 当PET不可用时,可考虑CT用于初始治疗监测。

研究设计与样本

  • 50例腹膜后纤维化患者至少接受两次[18F]FDG PET/CT(基线BL和第一次随访FU1),36例接受第二次随访(FU2),18例接受第三次随访(FU3)。
  • 测量PET参数SUVmax、SUVmean、SUVpeak、代谢活跃体积(MAV)以及腹膜后肿块的厚度(CTrim)和头尾延伸范围(CTcc)。
  • 治疗组分为泼尼松龙组、利妥昔单抗组及两者联合组。

主要发现

  • 所有PET参数在四个时间点均与CTrim显著相关。
  • 治疗后所有PET参数和CTrim均显著下降(p ≤ 0.021)。
  • 泼尼松龙组代谢与形态学反应高度显著(p ≤ 0.003),联合治疗组亦高度显著(p ≤ 0.001)。
  • FU2时8例进展,基线MAV是进展的良好预测因子(p = 0.041;进展组217.33 ml vs 非进展组100.86 ml)。
  • FU2时SUVmax、SUVpeak和MAV在进展组与非进展组间差异显著(p ≤ 0.009),而CT无显著差异。

关键数值与推荐

  • 治疗后所有PET参数和CTrim下降的显著性为p ≤ 0.021。
  • 泼尼松龙组代谢与形态学反应的显著性为p ≤ 0.003。
  • 联合治疗组代谢与形态学反应的显著性为p ≤ 0.001。
  • 基线MAV预测FU2进展的显著性为p = 0.041;进展组217.33 ml vs 非进展组100.86 ml。
  • FU2时SUVmax、SUVpeak和MAV在进展组与非进展组间差异的显著性为p ≤ 0.009。

临床怎么用

  • 作者认为PET在腹膜后纤维化治疗监测方面优于CT,尤其在FU2时检测进展方面。
  • 作者认为较高的基线MAV与FU2时进展相关,提示其作为预测标志物的潜力。
  • 作者认为当PET不可用时,可考虑CT用于初始治疗监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Retroperitoneal fibrosis (RPF) is a rare inflammatory disease, that, if left untreated, can lead to ureteral obstruction and subsequent renal impairment. First-line treatment is prednisolone, with rituximab, often used for refractory cases. This study evaluates treatment response in both [18F]FDG PET and CT, and potential baseline parameters for early prediction of progression. METHODS: 50 patients with RPF underwent at least two [18F]FDG PET/CT scans (baseline, BL, and first follow-up, FU1), 36 patients a second (FU2), 18 patients a third follow-up (FU3). PET parameters SUVmax, SUVmean, SUVpeak, metabolic active volume (MAV), thickness (CTrim) and cranio-caudal extension (CTcc) of the retroperitoneal mass were measured. Therapy groups were divided into prednisolone, rituximab and the combination of both. RESULTS: All PET parameters showed significant correlations with CTrim at all four timepoints. After therapy all PET parameters and CTrim decreased significantly (p ≤ 0.021). Highly significant metabolic and morphologic response was seen in the prednisolone (p ≤ 0.003) and the combination therapy group (p ≤ 0.001). At FU2, eight patients showed progression, with MAV as a good predictor of progression in BL (p = 0.041; 217.33 versus 100.86 ml). At FU2, SUVmax, SUVpeak and MAV differed significantly between progression and non-progression group (p ≤ 0.009), while CT showed no significant differences. CONCLUSION: Our findings underscore the superiority of PET against CT in therapy monitoring of RPF, especially in the detection of progression at FU2. Higher BL MAV correlated with progression at FU2, indicating its potential as a predictive marker. Still, especially when PET is not available, CT can be considered for initial therapy monitoring.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bayerl C, Kaufmann J, Metzger G, et al. [18F]FDG PET/CT for treatment monitoring and prediction of progression in retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40810802. doi:10.1007/s00259-025-07479-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。